Navigation Links
EntreMed to Present at The Rodman and Renshaw 5th Annual Global Healthcare Conference
Date:5/13/2008

ROCKVILLE, Md., May 13 /PRNewswire-FirstCall/ -- EntreMed, Inc. (Nasdaq: ENMD) a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer and inflammatory diseases, announced today that James S. Burns, President and Chief Executive Officer, will present a Company overview at the Rodman and Renshaw 5th Annual Global Healthcare Conference, to be held at the Le Meridien Beach Plaza Hotel in Monte Carlo, May 19-20, 2008. Mr. Burns' presentation is scheduled for Monday, May 19, 2008 at 10:25 a.m. (local time).

(Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO )

As previously mentioned, Mr. Burns' live presentation will be web cast and will serve as the Company's first quarter 2008 update. The presentation can be accessed through the Company's web site at http://www.entremed.com. An archive will be available on the web site for approximately 90 days.

About EntreMed

EntreMed, Inc. is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation. MKC-1 is currently in multiple Phase 2 clinical trials for cancer. MKC-1 is an oral cell-cycle regulator with activity against the mTOR pathway. ENMD-1198, a novel antimitotic agent, and ENMD-2076, a selective kinase inhibitor, are in Phase 1 studies in advanced cancers. The Company also has an approved IND application for Panzem(R) in rheumatoid arthritis. EntreMed's goal is to develop and commercialize new compounds based on the Company's expertise in angiogenesis, cell-cycle regulation and inflammation - processes vital to the treatment of cancer and other diseases, such as rheumatoid arthritis. Additional information about EntreMed is available on the Company's web site at http://www.entremed.com and in various filings with the Securities and Exchange Commission.

CONTACT:

Ginny Dunn

Associate Director

Corporate Communications &Investor Relations

EntreMed, Inc.

240-864-2643


'/>"/>
SOURCE EntreMed, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. EntreMed Reports First Quarter 2008 Financial Results
2. Dr. Ronald E. Cape to Retire from EntreMed Board of Directors
3. EntreMed to Present at the Jesup & Lamont Emerging Growth Stock Conference
4. EntreMed Announces FDA Acceptance of IND Application for Panzem(R) in Rheumatoid Arthritis
5. EntreMed Presents Results for ENMD-1198 and Vincristine in Preclinical Leukemia Models
6. EntreMed Reports Third Quarter 2007 Financial Results
7. EntreMed to Present at the Rodman and Renshaw 9th Annual Healthcare Conference
8. EntreMed Presents Results for Panzem(R) NCD Phase 2 Ovarian Cancer Study
9. EntreMed to Present at the Bio 2007 Investor Forum
10. EntreMed Receives Deloitte Technology Fast 50 Award
11. Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... ... May 05, 2016 , ... Einstein Medical is ... to cover the latest news and commentary at the 2016 ASCRS/ASOA Symposium and Congress, ... the American Society of Cataract and Refractive Surgery and the American Society of Ophthalmic ...
(Date:5/5/2016)... ... May 05, 2016 , ... ... offer patients with non-valvular atrial fibrillation (A-Fib) an alternative to long-term warfarin medication ... offering the procedure in April of 2015, Florida Hospital Pepin Heart Institute doctors ...
(Date:5/5/2016)... ... 05, 2016 , ... TLC Laser Eye Centers announced today that it has ... will now be called “Gordon Schanzlin New Vision Institute, a TLC Laser Eye Center.” ... facility to ensure that patients continue to receive the highest quality of care. In ...
(Date:5/5/2016)... ... ... weekend, from Friday, May 6 - Sunday, May 8, fifteen elite athletes from Team ... Fi Mountain Bike Camp, hosted in conjunction with WTB and Cannondale ... Moeschler, who’ll share pro tips with the injured veterans as they rip down some of ...
(Date:5/5/2016)... SAN FRANCISCO (PRWEB) , ... May 05, 2016 ... ... in the Unites States to promise successful results with IVF and with egg ... Designed to deliver the most patient-centric and highest quality fertility care, Spring Fertility ...
Breaking Medicine News(10 mins):
(Date:5/5/2016)... 5, 2016  Endo International plc (NASDAQ: ... Brian Lortie , President, U.S. Branded Pharmaceuticals, ... upon the appointment of a successor. Mr. Lortie ... Pharmaceuticals business with responsibility for all strategic, commercial ... and portfolio development, commercial operations, managed markets, manufacturing, ...
(Date:5/5/2016)... Endo International plc (NASDAQ: ENDP ) (TSX: ENL) ... former president of Allergan, Inc. and current CEO of Chase ... of TPG Capital, to its Board of Directors. The appointments ... "Endo recently embarked on a search for new Board members ... Doug and Todd are experienced leaders, and we are extremely ...
(Date:5/5/2016)... First quarter 2016 adjusted diluted earnings per share (EPS) ... First quarter reported diluted (GAAP) loss per share from ... 2016 financial guidance; now expects 2016 revenues to range from ... earnings per share to range from $4.50 to $4.80 ... manufacturing facility restructuring , Company expands Board ...
Breaking Medicine Technology: